Euroapi (EAPI) 주식 개요
유로아피는 인체 및 동물용 의약품의 제형에 사용되는 활성 의약품 성분과 중간체를 개발, 제조, 판매 및 유통하는 기업입니다. 자세히 보기
EAPI Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Euroapi S.A. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | €1.49 |
| 52주 최고가 | €3.57 |
| 52주 최저가 | €1.22 |
| 베타 | 0.96 |
| 1개월 변동 | 12.90% |
| 3개월 변동 | -30.66% |
| 1년 변동 | -50.17% |
| 3년 변동 | -85.28% |
| 5년 변동 | n/a |
| IPO 이후 변동 | -88.99% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 10
EAPI: Lower Expectations On 2026 Outlook Will Support Future Rebound Potential
Euroapi's analyst price target has shifted lower from about €3.08 to €2.00, with analysts pointing to Deutsche Bank's recent cut in its target to €1, along with updated views on revenue growth, profit margin, discount rate and future P/E assumptions. Analyst Commentary Bullish Takeaways Bullish analysts may see the lower price target range, now clustering around €1 to €2, as setting a more conservative bar for execution, which can reduce the risk of further valuation resets if expectations are now better aligned with current fundamentals.
내러티브 업데이트 • Apr 22
EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings
Analysts have cut their price target on Euroapi to €1 from €2, with the change framed around more cautious assumptions despite essentially unchanged fair value, discount rate, revenue growth, profit margin and future P/E inputs in the latest update. Analyst Commentary Bearish analysts cutting the price target on Euroapi to €1 from €2 are signaling a more cautious stance around the stock, even though their core valuation inputs such as fair value frameworks, discount rate, revenue growth, profit margin and future P/E assumptions are described as essentially unchanged.
내러티브 업데이트 • Apr 08
EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds
Analysts now see Euroapi's fair value closer to €2.90, down from €3.50, aligning with a series of lower Street price targets that most recently moved from €2.50 to €2 and then to €1. Analyst Commentary The recent cuts in fair value and Street targets to around €1 to €2 signal a cautious stance from research desks, with the most recent change bringing the target to €1 and maintaining a Sell view.내러티브 업데이트 • Mar 25
EAPI: Weaker 2026 Outlook And Portfolio Cuts Will Pressure Earnings Quality
Analysts have cut their price target on Euroapi to €1 from €2, with the shift broadly tied to ongoing caution reflected in recent research commentary that maintains a Sell stance and modest adjustments to revenue growth and profit margin assumptions. Analyst Commentary Recent research updates highlight a series of price target cuts on Euroapi, with bearish analysts reducing their fair value estimates while maintaining a cautious stance on the shares.Recent updates
내러티브 업데이트 • May 10
EAPI: Lower Expectations On 2026 Outlook Will Support Future Rebound Potential
Euroapi's analyst price target has shifted lower from about €3.08 to €2.00, with analysts pointing to Deutsche Bank's recent cut in its target to €1, along with updated views on revenue growth, profit margin, discount rate and future P/E assumptions. Analyst Commentary Bullish Takeaways Bullish analysts may see the lower price target range, now clustering around €1 to €2, as setting a more conservative bar for execution, which can reduce the risk of further valuation resets if expectations are now better aligned with current fundamentals.내러티브 업데이트 • Apr 22
EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings
Analysts have cut their price target on Euroapi to €1 from €2, with the change framed around more cautious assumptions despite essentially unchanged fair value, discount rate, revenue growth, profit margin and future P/E inputs in the latest update. Analyst Commentary Bearish analysts cutting the price target on Euroapi to €1 from €2 are signaling a more cautious stance around the stock, even though their core valuation inputs such as fair value frameworks, discount rate, revenue growth, profit margin and future P/E assumptions are described as essentially unchanged.내러티브 업데이트 • Apr 08
EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds
Analysts now see Euroapi's fair value closer to €2.90, down from €3.50, aligning with a series of lower Street price targets that most recently moved from €2.50 to €2 and then to €1. Analyst Commentary The recent cuts in fair value and Street targets to around €1 to €2 signal a cautious stance from research desks, with the most recent change bringing the target to €1 and maintaining a Sell view.내러티브 업데이트 • Mar 25
EAPI: Weaker 2026 Outlook And Portfolio Cuts Will Pressure Earnings Quality
Analysts have cut their price target on Euroapi to €1 from €2, with the shift broadly tied to ongoing caution reflected in recent research commentary that maintains a Sell stance and modest adjustments to revenue growth and profit margin assumptions. Analyst Commentary Recent research updates highlight a series of price target cuts on Euroapi, with bearish analysts reducing their fair value estimates while maintaining a cautious stance on the shares.내러티브 업데이트 • Mar 10
EAPI: Weaker 2025 Guidance Will Pressure Margins And Future Earnings Quality
Analysts have cut their Euroapi price target from €2 to €1, reflecting updated assumptions that now factor in lower revenue growth expectations, much slimmer profit margins, and a significantly higher future P/E multiple. Analyst Commentary Recent price target revisions point to a cautious stance from bearish analysts, who appear focused on execution risks and the implications for Euroapi's valuation.내러티브 업데이트 • Feb 24
EAPI: Lower 2025 Guidance And Reduced Multiple Will Shape Return Profile
Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing updated assumptions on modest revenue growth, slightly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent research points to a more cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.내러티브 업데이트 • Feb 09
EAPI: Lower 2025 Outlook And Cautious Stance Will Shape Return Profile
Analysts have lowered their price target on Euroapi from €2.50 to €2, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that collectively suggest a more cautious valuation stance. Analyst Commentary Bearish analysts have recently cut their price target on Euroapi from €2.50 to €2.내러티브 업데이트 • Jan 25
EAPI: Execution Risks And Lower Outlook Will Shape Future Return Profile
Narrative update Analysts have trimmed their price target on Euroapi by €0.50 to €2.00, citing updated assumptions on revenue growth, profit margins and forward P/E that keep their stance cautious on the shares. Analyst Commentary Recent research has reinforced a cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.00.내러티브 업데이트 • Jan 10
EAPI: Lower Profitability Assumptions And New Partnership Will Shape Future Returns
Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing softer assumptions around revenue growth, profit margins and a higher future P/E multiple as the key drivers of the reset. Analyst Commentary Bearish analysts are signalling a cautious stance on Euroapi by aligning around a lower price target of €2, narrowed from €2.50.내러티브 업데이트 • Dec 19
EAPI: Higher Discount Rate Will Outweigh Benefits From New Corticosteroid Partnership
Analysts have slightly reduced their Euroapi price target, reflecting a modest reassessment of fair value. This adjustment accounts for a higher discount rate, even as long term profit margin assumptions edge up and revenue declines appear marginally less severe.분석 기사 • Dec 18
Calculating The Intrinsic Value Of Euroapi S.A. (EPA:EAPI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €2.68 Euroapi's €2.40 share...분석 기사 • Dec 18
Euroapi S.A. (EPA:EAPI) Not Doing Enough For Some Investors As Its Shares Slump 26%
Euroapi S.A. ( EPA:EAPI ) shareholders that were waiting for something to happen have been dealt a blow with a 26...분석 기사 • Oct 03
Euroapi (EPA:EAPI) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Aug 02
Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates
It's been a mediocre week for Euroapi S.A. ( EPA:EAPI ) shareholders, with the stock dropping 12% to €2.79 in the week...
새로운 내러티브 • Mar 31
Capacity Expansion And Efficiency Improvements Will Shape Future Success
Euroapi focuses on high-margin differentiated APIs and CDMO services to boost sustainable revenue and profit margins through strategic project expansions.분석 기사 • Mar 06
Analyst Estimates: Here's What Brokers Think Of Euroapi S.A. (EPA:EAPI) After Its Annual Report
It's been a good week for Euroapi S.A. ( EPA:EAPI ) shareholders, because the company has just released its latest...분석 기사 • Oct 04
Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 25% Below Its Share Price
Key Insights The projected fair value for Euroapi is €2.62 based on 2 Stage Free Cash Flow to Equity Current share...분석 기사 • Jul 29
There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise
Euroapi S.A. ( EPA:EAPI ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...분석 기사 • May 24
Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Those holding Euroapi S.A. ( EPA:EAPI ) shares would be relieved that the share price has rebounded 29% in the last...분석 기사 • Apr 10
Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Mar 03
Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding
The Euroapi S.A. ( EPA:EAPI ) share price has fared very poorly over the last month, falling by a substantial 31%. For...분석 기사 • Mar 02
Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a major selloff in Euroapi S.A. ( EPA:EAPI ) shares in the week since it released its yearly report, with...분석 기사 • Dec 21
A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €5.03 With €5.47 share price...분석 기사 • Aug 04
Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results
It's been a good week for Euroapi S.A. ( EPA:EAPI ) shareholders, because the company has just released its latest...분석 기사 • Aug 02
Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €24.50 Euroapi is estimated to...분석 기사 • Jun 16
Euroapi S.A.'s (EPA:EAPI) Subdued P/S Might Signal An Opportunity
When close to half the companies operating in the Pharmaceuticals industry in France have price-to-sales ratios (or...분석 기사 • Jan 25
An Intrinsic Calculation For Euroapi S.A. (EPA:EAPI) Suggests It's 37% Undervalued
Key Insights Euroapi's estimated fair value is €21.9 based on 2 Stage Free Cash Flow to Equity Current share price of...주주 수익률
| EAPI | FR Pharmaceuticals | FR 시장 | |
|---|---|---|---|
| 7D | -0.8% | -2.0% | 1.1% |
| 1Y | -50.2% | -8.6% | 2.0% |
수익률 대 산업: EAPI은 지난 1년 동안 -8.6%의 수익을 기록한 French Pharmaceuticals 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: EAPI은 지난 1년 동안 2%를 기록한 French 시장보다 저조한 성과를 냈습니다.
주가 변동성
| EAPI volatility | |
|---|---|
| EAPI Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in FR Market | 11.0% |
| 10% least volatile stocks in FR Market | 2.9% |
안정적인 주가: EAPI의 주가는 지난 3개월 동안 French 시장보다 변동성이 컸습니다.
시간에 따른 변동성: EAPI의 주간 변동성(9%)은 지난 1년 동안 안정적이었지만 French 종목 중 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2020 | 2,961 | David Seignolle | www.euroapi.com/en |
유로아피는 인체 및 동물용 의약품 제형에 사용되는 활성 제약 성분과 중간체를 개발, 제조, 판매 및 유통합니다. 이 회사는 고상 화학, 입자 공학, 미생물 발효, 저분자 합성, 프로스타글란딘, 스테로이드 및 호르몬, 아편제 및 규제 물질, 지질을 사용하는 다양한 종류의 조류를 위한 위탁 개발 제조 조직을 제공합니다. 이 회사는 제약, 일반 의약품 제조업체, 동물 건강 제품 제조업체, 소비자 건강, 영양 및 화장품 회사, 생명공학 회사, 유통 회사, 계약 개발 및 제조 조직에 제품을 제공합니다.
Euroapi S.A. 기초 지표 요약
| EAPI 기초 통계 | |
|---|---|
| 시가총액 | €141.64m |
| 순이익 (TTM) | -€211.20m |
| 매출 (TTM) | €852.60m |
0.2x
주가매출비율(P/S)-0.7x
주가수익비율(P/E)EAPI는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| EAPI 손익계산서 (TTM) | |
|---|---|
| 매출 | €852.60m |
| 매출원가 | €707.70m |
| 총이익 | €144.90m |
| 기타 비용 | €356.10m |
| 순이익 | -€211.20m |
최근 보고된 실적
Dec 31, 2025
다음 실적 발표일
Jul 28, 2026
| 주당순이익(EPS) | -2.22 |
| 총이익률 | 17.00% |
| 순이익률 | -24.77% |
| 부채/자본 비율 | 5.8% |
EAPI의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/29 16:01 |
| 종가 | 2026/05/29 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Euroapi S.A.는 11명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Justin Steven Smith | Bernstein |
| Patrick Andrew Wood | BofA Global Research |
| Fynn Scherzler | Deutsche Bank |